AbbVie registers three new trials spanning obesity, head and neck cancer, and atopic dermatitis

AbbVie posted three new trial registrations this week across metabolic, oncology, and dermatology programs.

• ABBV-295, an investigational long-acting amylin analog, entered a Phase 2 dose-finding study in adults with obesity or overweight and weight-related comorbidities, now recruiting. ABBV-295 is an investigational long-acting amylin analog being developed for chronic weight management, and the study is evaluating various doses against placebo for reducing body weight at Week 32.¹ The trial plans to enroll approximately 360 participants at about 70 sites in the United States and Puerto Rico.¹
• Telisotuzumab adizutecan, paired with pembrolizumab, moved into a Phase 2 study for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, not yet recruiting. Enrollment will include adult participants diagnosed with recurrent or metastatic HNSCC who have not received prior systemic therapy for advanced disease and whose tumors express c-Met protein.² Enrollment is estimated at 150 participants.²
• A new observational study called RAMpUp will track real-world use of upadacitinib and biologics in moderate-to-severe atopic dermatitis, not yet recruiting. The primary outcome is the percentage of participants achieving minimal disease activity at Week 16, defined by an EASI score of 3 or less and a Worst Pruritus Numerical Rating Scale of 0 or 1.³ The study plans to enroll around 900 participants at multiple sites worldwide.³